Wijsenbeek MS, Floricel F, Thonnard J, et al. A worldwide review of ‘real’ life’ practice: experience from a treatment feasibility review in 41 countries. ERS 2018, Parijs. Sessie 46; OA263.
Amivantamab-lazertinib beter dan osimertinib bij NSCLC met EGFR-mutatie
feb 2026 | Longoncologie